Table 2.

Trials Associated with Nasopharyngeal Carcinoma and Immune-Checkpoint Inhibitor

ICIs as neoadjuvant and adjuvant chemotherapy
NCT03925090 Phase 2	Cisplatin + Toripalimab or placebo	Stage III-IVa NPC	Neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with CCRT vs CCRT plus placebo
NCT05397769 Phase 2	Envafolimab + CRT	Locally advanced NPC	ICT: 3 cycles of GP+ Envafolimab CCRT: IMRT 68–70Gy/30–33f + 2 cycles of Cisplatin + Envafolimab Maintenance treatment: Envafolimab every 3 weeks for a year
NCT04833257 Phase 2	Gemcitabine Cisplatin Tislelizumab	Locally advanced NPC	Neoadjuvant therapy: Gemcitabine/Cisplatin + Tislelizumab
NCT04907370 Phase 3	Toripalimab Gemcitabine Cisplatin	Locoregionally Advanced NPC	ICT: Toripalimab + Cisplatin or Gemcitabine
NCT03984357 Phase 2	Nivolumab Gemcitabine Cisplatin	Locoregionally Advanced NPC	ICT: Nivolmab+gemcitabine-cisplatin RT: IMRT + Nivolmab
ICI with PARP inhibitor
NCT04825990 Phase 2	Pembrolizumab Orapalib	Recurrent/Metastatic NPC	PARP inhibitor (Olaparib) + PD-1 antibody (Pembrolizumab)
NCT04978012 Phase 2	Fluzoparib Camrelizumab	Recurrent/Metastatic NPC	PARP inhibitor (Fluzoparib) + PD-1 antibody (Camrelizumab)
NCT05162872 Phase 2	Niraparib, Sintilimab	Recurrent/Metastatic NPC	PARP inhibitor (Niraparib) + PD-1 antibody (Sintilimab)

Abbreviations: ICI, immune-check point inhibitor; NPC, nasopharyngeal carcinoma; CCRT, concurrent chemoradiotherapy; ICT, induction chemotherapy; RT, radiotherapy; IMRT, intensity modulated radiation therapy; PARP, poly ADP ribose polymerase; PD-1, Programmed cell death 1.